Suppr超能文献

GNAS 敲除通过病毒模拟相关的干扰素反应增强淋巴瘤中 HDAC3 的抑制作用。

GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma.

机构信息

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Department of Immunology, University of Toronto, Toronto, ON, Canada.

出版信息

Leukemia. 2024 Oct;38(10):2210-2224. doi: 10.1038/s41375-024-02325-4. Epub 2024 Aug 8.

Abstract

Despite selective HDAC3 inhibition showing promise in a subset of lymphomas with CREBBP mutations, wild-type tumors generally exhibit resistance. Here, using unbiased genome-wide CRISPR screening, we identify GNAS knockout (KO) as a sensitizer of resistant lymphoma cells to HDAC3 inhibition. Mechanistically, GNAS KO-induced sensitization is independent of the canonical G-protein activities but unexpectedly mediated by viral mimicry-related interferon (IFN) responses, characterized by TBK1 and IRF3 activation, double-stranded RNA formation, and transposable element (TE) expression. GNAS KO additionally synergizes with HDAC3 inhibition to enhance CD8 T cell-induced cytotoxicity. Moreover, we observe in human lymphoma patients that low GNAS expression is associated with high baseline TE expression and upregulated IFN signaling and shares common disrupted biological activities with GNAS KO in histone modification, mRNA processing, and transcriptional regulation. Collectively, our findings establish an unprecedented link between HDAC3 inhibition and viral mimicry in lymphoma. We suggest low GNAS expression as a potential biomarker that reflects viral mimicry priming for enhanced response to HDAC3 inhibition in the clinical treatment of lymphoma, especially the CREBBP wild-type cases.

摘要

尽管选择性 HDAC3 抑制在具有 CREBBP 突变的部分淋巴瘤中显示出前景,但野生型肿瘤通常表现出耐药性。在这里,我们使用无偏基因组范围的 CRISPR 筛选,鉴定出 GNAS 敲除(KO)是对 HDAC3 抑制有抗性的淋巴瘤细胞的敏化剂。从机制上讲,GNAS KO 诱导的敏化作用不依赖于经典 G 蛋白活性,但出乎意料的是通过病毒模拟相关干扰素(IFN)反应介导,其特征是 TBK1 和 IRF3 激活、双链 RNA 形成和转座元件(TE)表达。GNAS KO 还与 HDAC3 抑制协同作用,增强 CD8 T 细胞诱导的细胞毒性。此外,我们在人类淋巴瘤患者中观察到,低 GNAS 表达与高基线 TE 表达和上调的 IFN 信号相关,并且与 GNAS KO 在组蛋白修饰、mRNA 处理和转录调控方面具有共同的破坏生物学活性。总之,我们的发现在淋巴瘤中建立了 HDAC3 抑制与病毒模拟之间前所未有的联系。我们建议低 GNAS 表达作为一个潜在的生物标志物,反映了病毒模拟的启动,以增强对 HDAC3 抑制的反应,在淋巴瘤的临床治疗中,特别是 CREBBP 野生型病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/484b/11436380/a3f96b363e4f/41375_2024_2325_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验